This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (1)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Topic Collections  • Oncology  • Drug Therapy, Other  • Gastroenterology  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

One Small Step Forward

Al B. Benson III, MD

JAMA. 2007;297:311-313.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The great tragedy facing the majority of patients with newly diagnosed adenocarcinoma of the pancreas is the persistent high rate of lethality:most newly diagnosed individuals will die within a year.¹ Approximately 20% of patients are considered for surgical therapy; however, only about half of these individuals undergo successful resections.^2-4 Surgery remains the only opportunity for cure and can be performed with significant reduction in rates of operative morbidity and mortality, particularly at experienced high-volume centers.⁵ Use of neoadjuvant strategies in the preoperative setting to improve surgical resectability remain experimental. Adjuvant therapy for the postoperative pancreatic cancer patient has been a highly controversial topic with some strong differences in opinions about the use of adjuvant radiation, chemotherapy, or combined chemoradiation, particularly between investigators in the United States and Europe.^6-7

In this issue of JAMA, Oettle et al present the results of CONKO-001, a well-designed randomized . . . [Full Text of this Article]

Author Affiliations: Department of Medicine, Division of Hematology/Oncology, Feinberg School of Medicine, Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Ill.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Adjuvant Chemotherapy With Gemcitabine vs Observation in Patients Undergoing Curative-Intent Resection of Pancreatic Cancer: A Randomized Controlled Trial
Helmut Oettle, Stefan Post, Peter Neuhaus, Klaus Gellert, Jan Langrehr, Karsten Ridwelski, Harald Schramm, Joerg Fahlke, Carl Zuelke, Christof Burkart, Klaus Gutberlet, Erika Kettner, Harald Schmalenberg, Karin Weigang-Koehler, Wolf-Otto Bechstein, Marco Niedergethmann, Ingo Schmidt-Wolf, Lars Roll, Bernd Doerken, and Hanno Riess
JAMA. 2007;297(3):267-277.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report
Duffy et al.
Ann Oncol 2009;0:mdp332v2-mdp332.
ABSTRACT | FULL TEXT  

Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma: A Randomized Controlled Trial
Regine et al.
JAMA 2008;299:1019-1026.
ABSTRACT | FULL TEXT